|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||17.20 / 28.45|
An inverse head-and-shoulders pattern has formed, suggesting a bullish reversal.
Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.
Jim Cramer is bullish on MGM Resorts, Baozun, DowDuPont, and Wynn Resorts.
The insurgent investor explains that he believes the payroll company's problems are yet to come.
Breaking below the $20 for the first time in years is a warning signal.
A stock that has been above $20 for years and then slips below $20 has a hard time finding new buyers.
A stock that has been above $20 for years, and then slips below $20, has a hard time finding new buyers.
Can the beleaguered investor turn things around?
It certainly looks like 2017 is shaping up to be another "terrible, horrible, no good, very bad" year.
A mutual fund filed the lawsuit Wednesday.
For his 'Executive Decision' segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant
The dispute became the center of a drug price firestorm.
What's next for Valeant Pharmaceuticals shares?
Jim Cramer says despite chaos in Washington, the market's not falling. Why? Because stocks aren't a referendum on the presidency.
Joe Papa, chairman and CEO of Valeant Pharmaceuticals International, talks to Jim Cramer about his company's turnaround.
Here's what you need to know now for Wed., Aug. 9.
The Laval, Quebec-based pharmaceutical company updated its revenue guidance and maintained its adjusted Ebitda outlook.
Here's what you need to know now for Tuesday, Aug. 8.
Amgen, Compugen and Foundation Medicine were among the biotech stock movers in premarket trading on July 26.
FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8.
U.S. stock futures point to a lower open for Wall Street on Tuesday.
The focus remains on earnings while the season winds down.
The UN Security Council unanimously voted Saturday to sanction North Korea for ballistic missile tests, but currencies and futures barely budged.
As Ackman's fund, Pershing Square, pushing for control of the board at ADP, the company highlights that the fund has underperformed ADP in recent years.
Here's what you need to know now for Thursday, Aug. 3.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.